Fresenius Medical Care (NYSE:FMS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note released on Monday. The firm issued a strong-buy rating on the stock.

Separately, Truist Financial reduced their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $22.00.

Fresenius Medical Care Stock Down 0.1 %

Shares of FMS opened at $21.29 on Monday. The firm has a market cap of $12.49 billion, a P/E ratio of 23.92, a PEG ratio of 1.08 and a beta of 0.90. Fresenius Medical Care has a 12 month low of $16.37 and a 12 month high of $22.76. The stock’s 50 day moving average is $19.71 and its two-hundred day moving average is $19.96. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting the consensus estimate of $0.38. The company had revenue of $5.13 billion during the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. Analysts predict that Fresenius Medical Care will post 1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in shares of Fresenius Medical Care by 21.8% in the first quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after buying an additional 758 shares during the last quarter. Wulff Hansen & CO. raised its holdings in Fresenius Medical Care by 1,809.0% in the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares during the last quarter. QRG Capital Management Inc. lifted its stake in Fresenius Medical Care by 19.5% in the 1st quarter. QRG Capital Management Inc. now owns 54,363 shares of the company’s stock worth $1,048,000 after purchasing an additional 8,870 shares in the last quarter. SG Americas Securities LLC boosted its holdings in shares of Fresenius Medical Care by 50.0% during the 1st quarter. SG Americas Securities LLC now owns 15,228 shares of the company’s stock worth $294,000 after purchasing an additional 5,078 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC purchased a new stake in shares of Fresenius Medical Care in the first quarter valued at approximately $584,000. Hedge funds and other institutional investors own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.